Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318278 | 0.87 | HTT (0.44) | GAANPSR1NR3C1ALDH1A1LMNA | |
| SCHEMBL6316740 | 0.87 | ALDH1A1 (0.46) | SMN1; SMN2NPSR1ALDH1A1LMNANPC1 | |
| SCHEMBL6321867 | 0.85 | WNT3A (0.41) | SMN1; SMN2GAANPSR1ALDH1A1LMNA | |
| SCHEMBL6315001 | 0.84 | ALDH1A1 (0.44) | SMN1; SMN2GAAP2RX7NR3C1ALDH1A1 | |
| SCHEMBL6315794 | 0.83 | KDM4E (0.49) | SMN1; SMN2GAANPSR1ALDH1A1LMNA | |
| SCHEMBL6315445 | 0.82 | WNT3A (0.43) | SMN1; SMN2GAANPSR1LMNANPC1 | |
| SCHEMBL6322626 | 0.80 | NPC1 (0.48) | SMN1; SMN2NPSR1ALDH1A1LMNANPC1 | |
| SCHEMBL6316394 | 0.80 | KMT2A (0.48) | SMN1; SMN2NR3C1ALDH1A1LMNANPC1 | |
| SCHEMBL6315832 | 0.80 | CA1 (0.43) | SMN1; SMN2GAANPSR1NR3C1ALDH1A1 | |
| SCHEMBL6316791 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2NR3C1ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| US-6906185-B1 | Derivatives of 7-deaza -2′-deoxyguanosine-5'-triphosphate, preparation and use thereof | AMERSHAM BIOSCIENCES CORP. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | SMN1; SMN2 2766/4885GAA 789/4885NPSR1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.